Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miklos Feher

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry|March 22, 2005
In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptorJonathan M Schmidt, Gilles B Tremblay, Michael A Plastina, et al.
Journal of Medicinal Chemistry|April 4, 2003
De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptorJonathan M Schmidt, Julie Mercure, Gilles B Tremblay, et al.
Bioorganic & Medicinal Chemistry|June 15, 2007
Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonistsMarion C Lanier, Miklos Feher, Neil J Ashweek, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2016
Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacySze-Wan Li, Yong Liu, Peter B Sampson, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2016
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTKRadoslaw Laufer, Sze-Wan Li, Yong Liu, et al.
Journal of Medicinal Chemistry|July 9, 2013
The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agentsRadoslaw Laufer, Bryan Forrest, Sze-Wan Li, et al.
Journal of Medicinal Chemistry|May 29, 2014
The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agentsPeter B Sampson, Yong Liu, Narendra Kumar Patel, et al.
Journal of Medicinal Chemistry|February 28, 2015
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agentPeter B Sampson, Yong Liu, Bryan Forrest, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer AgentYong Liu, Radoslaw Laufer, Narendra Kumar Patel, et al.
Bioorganic & Medicinal Chemistry|July 22, 2014
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamidesRadoslaw Laufer, Grace Ng, Yong Liu, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry|March 22, 2005
In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptorJonathan M Schmidt, Gilles B Tremblay, Michael A Plastina, et al.
Journal of Medicinal Chemistry|April 4, 2003
De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptorJonathan M Schmidt, Julie Mercure, Gilles B Tremblay, et al.
Bioorganic & Medicinal Chemistry|June 15, 2007
Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonistsMarion C Lanier, Miklos Feher, Neil J Ashweek, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2016
Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacySze-Wan Li, Yong Liu, Peter B Sampson, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2016
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTKRadoslaw Laufer, Sze-Wan Li, Yong Liu, et al.
Journal of Medicinal Chemistry|July 9, 2013
The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agentsRadoslaw Laufer, Bryan Forrest, Sze-Wan Li, et al.
Journal of Medicinal Chemistry|May 29, 2014
The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agentsPeter B Sampson, Yong Liu, Narendra Kumar Patel, et al.
Journal of Medicinal Chemistry|February 28, 2015
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agentPeter B Sampson, Yong Liu, Bryan Forrest, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer AgentYong Liu, Radoslaw Laufer, Narendra Kumar Patel, et al.
Bioorganic & Medicinal Chemistry|July 22, 2014
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamidesRadoslaw Laufer, Grace Ng, Yong Liu, et al.
Pageof 4